Overexpression of somatostatin receptor type 2 in neuroendocrine tumors for improved Ga68-DOTATATE imaging and treatment

Keyphrases

• Clinical Efficacy 10%
• Current Imaging 10%
• DOTATATE 100%
• Fluorescence-activated Cell Sorting 10%
• Functional Expression 10%
• Histone Deacetylase Inhibitor (HDACi) 60%
• Imaging Standards 10%
• In Vitro Experiment 10%
• Inhibitor Treatment 10%
• MRNA Level 10%
• Neuroendocrine Tumor 100%
• Neuroendocrine Tumor Cell Lines 20%
• Overexpressing 10%
• Overexpression 100%
• Pancreas 10%
• Poorly Differentiated Neuroendocrine Tumors 10%
• Positron Emission Tomography-computed Tomography (PET-CT) 40%
• Protein Expression 10%
• Protein Level 10%
• Radiolabeled Somatostatin Analogs 10%
• Radiopeptide 10%
• Small Animal 20%
• Somatostatin Receptor 2 (SSTR2) 100%
• Sorting Analysis 10%
• Transcription Expression 10%
• Tumor 10%
• Tumor Xenograft 10%

Medicine and Dentistry

• Fluorescence Activated Cell Sorting 10%
• Gallium 68 100%
• Histone Deacetylase Inhibitor 60%
• In Vitro 10%
• Neoplasm 10%
• Neuroendocrine Tumor 100%
• Neuroendocrine Tumor Cell Line 20%
• Positron Emission Tomography-Computed Tomography 40%
• Protein Expression 10%
• Receptor Subtype 90%
• Somatostatin Derivative 10%
• Somatostatin Receptor 100%
• Tumor Xenograft 10%